MGMT and glioblastoma: Recently, we characterized the positive prognostic value of methylation of the Transforming Growth Factor Beta 2 (TGFB2) gene (hazard ratio (HR) (95% CI range) = 0.04 (0.006–0.274); p = 0.001), which was greater than the well-established impact of the O-6-Methylguanine-DNA Methyltransferase (MGMT) gene methylation (HR (95% CI range) = 0.667 (0.475–0.936); p = 0.019) interrogating the TCGA dataset for glioblastoma patients [30].